GSK shares surge after reaching settlement on Zantac ahead of California trial
GSK GSK shares surged 6% in London action as the U.K. pharmaceutical said it reached a settlement over its Zantac heartburn medication litigation with a plaintiff in California ahead of the trial slated to start July 24 in state court. Other companies impacted by Zantac litigation fears, Haleon and Sanofi , also advanced though not by as much. GSK didn't say the financial terms of the settlement but did say it did not admit liability. "We continue to believe the current share price reflects potential liabilities of up to [$30 billion] are being priced into the share," said analysts at Shore Capital. "Working backwards from this implies individual settlements at c.$225k which seems towards the higher end of pay-outs made in talc or glyphos cancer-related suits."
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
06-23-23 0501ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations